The best way to value IVX Photosoft cancer pre-clinical results is to compare it to IMU's CF33 Oncolytic Virus. Taking just the trial results into account and no combinations, like at IMU, the value should be USD 500m, about AUD 700m. That would be about 10c.
Considering just half of that, 5c would be justified.
But the market may hesitate as the board isn't really promoting the results in the science world and financial markets. As I pointed out before, IMU's management is made up by business / science people, IVX just got Dr Stephens as medical professional. Plus some people see the distribution agreement as a problem. But these things can be put aside by the market in a blink of an eye if the next results are stunning as well.
High Risk vs Very Very Very High Reward.
Bought 1m oppies yesterday at 0.3c to be covered, added 1m oppies at 0.2c today. No advice or attempt to lure anyone into oppie buying but with heads at 2.1c atm worth considering.
GLTA
IVX Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)